These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

397 related items for PubMed ID: 1379376

  • 1. Hydroxyurea and erythropoietin therapy in sickle cell anemia.
    Goldberg MA, Brugnara C, Dover GJ, Schapira L, Lacroix L, Bunn HF.
    Semin Oncol; 1992 Jun; 19(3 Suppl 9):74-81. PubMed ID: 1379376
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
    Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW.
    N Engl J Med; 1993 Jan 14; 328(2):73-80. PubMed ID: 7677965
    [Abstract] [Full Text] [Related]

  • 4. Spectrum of fetal hemoglobin responses in sickle cell patients treated with hydroxyurea: the National Institutes of Health experience.
    Rodgers GP.
    Semin Oncol; 1992 Jun 14; 19(3 Suppl 9):67-73. PubMed ID: 1379375
    [Abstract] [Full Text] [Related]

  • 5. The pharmacological manipulation of fetal haemoglobin: trials using hydroxyurea and recombinant human erythropoietin.
    el-Hazmi MA, al-Momen A, Warsy AS, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F.
    Acta Haematol; 1995 Jun 14; 93(2-4):57-61. PubMed ID: 7543719
    [Abstract] [Full Text] [Related]

  • 6. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.
    Medicine (Baltimore); 1996 Nov 14; 75(6):300-26. PubMed ID: 8982148
    [Abstract] [Full Text] [Related]

  • 7. Hydroxyurea-induced HbF production in anemic primates: augmentation by erythropoietin, hematopoietic growth factors, and sodium butyrate.
    McDonagh KT, Dover GJ, Donahue RE, Nathan DG, Agricola B, Byrne E, Nienhuis AW.
    Exp Hematol; 1992 Nov 14; 20(10):1156-64. PubMed ID: 1385194
    [Abstract] [Full Text] [Related]

  • 8. Hydroxyurea in the treatment of sickle-cell anemia.
    Howard LW, Kennedy LD.
    Ann Pharmacother; 1997 Nov 14; 31(11):1393-6. PubMed ID: 9391697
    [Abstract] [Full Text] [Related]

  • 9. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea.
    Rodgers GP, Dover GJ, Noguchi CT, Schechter AN, Nienhuis AW.
    N Engl J Med; 1990 Apr 12; 322(15):1037-45. PubMed ID: 1690857
    [Abstract] [Full Text] [Related]

  • 10. Enhancing Effect of Hydroxyurea on Hb F in Sickle Cell Disease: Ten-Year Egyptian Experience.
    Youssry I, Abdel-Salam A, Ismail R, Bou-Fakhredin R, Mohamed Samy R, Ezz El-Deen F, Taher AT.
    Hemoglobin; 2017 Apr 12; 41(4-6):267-273. PubMed ID: 29251012
    [Abstract] [Full Text] [Related]

  • 11. Effects of hydroxyurea on hemoglobin F and water content in the red blood cells of dogs and of patients with sickle cell anemia.
    Orringer EP, Blythe DS, Johnson AE, Phillips G, Dover GJ, Parker JC.
    Blood; 1991 Jul 01; 78(1):212-6. PubMed ID: 1712641
    [Abstract] [Full Text] [Related]

  • 12. Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease.
    Gordeuk VR, Campbell A, Rana S, Nouraie M, Niu X, Minniti CP, Sable C, Darbari D, Dham N, Onyekwere O, Ammosova T, Nekhai S, Kato GJ, Gladwin MT, Castro OL.
    Blood; 2009 Nov 19; 114(21):4639-44. PubMed ID: 19724057
    [Abstract] [Full Text] [Related]

  • 13. Cellular effects of hydroxyurea in Hb SC disease.
    Steinberg MH, Nagel RL, Brugnara C.
    Br J Haematol; 1997 Sep 19; 98(4):838-44. PubMed ID: 9326175
    [Abstract] [Full Text] [Related]

  • 14. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia.
    Ballas SK, McCarthy WF, Guo N, Brugnara C, Kling G, Bauserman RL, Waclawiw MA.
    Hemoglobin; 2010 Sep 19; 34(5):424-9. PubMed ID: 20854115
    [Abstract] [Full Text] [Related]

  • 15. Hydroxyurea therapy in children severely affected with sickle cell disease.
    Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ.
    J Pediatr; 1996 Jun 19; 128(6):820-8. PubMed ID: 8648542
    [Abstract] [Full Text] [Related]

  • 16. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
    el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.
    Acta Haematol; 1995 Jun 19; 94(3):128-34. PubMed ID: 7502628
    [Abstract] [Full Text] [Related]

  • 17. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea.
    Styles LA, Lubin B, Vichinsky E, Lawrence S, Hua M, Test S, Kuypers F.
    Blood; 1997 Apr 01; 89(7):2554-9. PubMed ID: 9116302
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.
    Blood Cells Mol Dis; 2000 Oct 01; 26(5):453-66. PubMed ID: 11112383
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.